Pharvaris N.V. Ordinary Shares (PHVS)

Price$29.10

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)8.70%

Price vs S&P 500 (4W)-2.53%

VGM Score83.98

Market Capitalization$2.44B

All Metrics

Book Value / Share (Quarterly)$4.21

P/TBV (Annual)4.24x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.63

Price vs S&P 500 (YTD)-2.25%

EPS (TTM)$-3.20

10-Day Avg Trading Volume0.29M

EPS Excl Extra (TTM)$-3.20

EPS (Annual)$-3.46

ROI (Annual)-64.58%

Cash / Share (Quarterly)$4.40

ROA (Last FY)-58.28%

EBITD / Share (TTM)$-3.23

ROE (5Y Avg)-42.63%

Cash Flow / Share (Annual)$-2.45

P/B Ratio7.58x

P/B Ratio (Quarterly)6.71x

Net Income / Employee (Annual)$-1,587,170

Net Interest Coverage (TTM)-45.75x

ROA (TTM)-60.74%

EPS Incl Extra (Annual)$-3.46

Current Ratio (Annual)10.11x

Quick Ratio (Quarterly)10.99x

3-Month Avg Trading Volume0.23M

52-Week Price Return80.38%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.76

52-Week High$33.33

EPS Excl Extra (Annual)$-3.46

CapEx CAGR (5Y)32.70%

26-Week Price Return24.63%

Quick Ratio (Annual)10.01x

13-Week Price Return7.71%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.24x

Enterprise Value$1.80B

Revenue / Employee (Annual)$0

Cash / Share (Annual)$5.21

3-Month Return Std Dev49.85%

Net Income / Employee (TTM)$-1,522,728

ROE (Last FY)-64.77%

Net Interest Coverage (Annual)-9.83x

EPS Basic Excl Extra (Annual)$-3.46

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.20

ROI (TTM)-66.96%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.63

Price vs S&P 500 (52W)52.18%

Year-to-Date Return8.68%

5-Day Price Return1.62%

EPS Normalized (Annual)$-3.46

ROA (5Y Avg)-39.06%

Month-to-Date Return-2.74%

Cash Flow / Share (TTM)$-3.65

EBITD / Share (Annual)$-3.34

LT Debt / Equity (Annual)0.17x

ROI (5Y Avg)-42.52%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-3.20

P/TBV (Quarterly)4.13x

P/B Ratio (Annual)5.62x

Book Value / Share (Annual)$4.85

Price vs S&P 500 (13W)-2.03%

Beta-2.49x

Revenue / Share (TTM)$0.00

ROE (TTM)-67.14%

52-Week Low$15.51

mGradeA

vgmGradeA

Show chart for

Earnings Surprise History

Q1 26-0.69est. -0.85

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.33

4.26

4.35

About

Pharvaris is a late-stage biopharmaceutical company developing deucrictibant, an oral bradykinin B2 receptor antagonist designed to prevent and treat hereditary angioedema (HAE) attacks. The company has demonstrated positive efficacy data in Phase 2 studies and is currently enrolling pivotal Phase 3 trials for both treatment and prevention indications.